APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drug Stability Testing

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Drug Stability Testing Market Analysis and Forecast 2026-2032

12 April 2026233 pages

Choose your research edition.

Industry ResearchDrug Stability Testing Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Drug Stability Testing Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Drug Stability Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drug Stability Testing Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Drug Stability Testing Market Analysis and Forecast 2026-2032233 pages · $4,950 USD

Market perspective

The global Drug Stability Testing market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Drug Stability Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Drug Stability Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Drug Stability Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Drug Stability Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Drug Stability Testing include Q Laboratories, Eurofins BioPharma, Intertek Group, Labcorp, Charles River Laboratories, SGS, Pacific BioLabs, Element Materials Technology and Catalent, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Drug Stability Testing, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Drug Stability Testing, also provides the revenue of main regions and countries. Of the upcoming market potential for Drug Stability Testing, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Drug Stability Testing revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Drug Stability Testing market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Drug Stability Testing revenue, projected growth trends, production technology, application and end-user industry.

Drug Stability Testing Segment by Company

Q Laboratories

Eurofins BioPharma

Intertek Group

Labcorp

Charles River Laboratories

SGS

Pacific BioLabs

Element Materials Technology

Catalent

Nelson Labs

PerkinElmer

BioProcess International

Ardena

Selvita

Alcami

Drug Stability Testing Segment by Type

Drug Substances

Finished Drug

Drug Stability Testing Segment by Application

Pharmaceutical Companies

Biopharmaceutical and Vaccine Companies

Advanced Therapies Companies

Others

Drug Stability Testing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drug Stability Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drug Stability Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drug Stability Testing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Drug Stability Testing in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Drug Stability Testing company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drug Stability Testing revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Drug Stability Testing Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Drug Substances Major Player Table 3. Finished Drug Major Player Table 4. Global Drug Stability Testing Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Pharmaceutical Companies Major Player Table 6. Biopharmaceutical and Vaccine Companies Major Player Table 7. Advanced Therapies Companies Major Player Table 8. Others Major Player Table 9. Drug Stability Testing Industry Trends Table 10. Drug Stability Testing Industry Drivers Table 11. Drug Stability Testing Industry Opportunities and Challenges Table 12. Drug Stability Testing Industry Restraints Table 13. Global Drug Stability Testing Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Drug Stability Testing Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Drug Stability Testing Market Share by Region (2021-2026) Table 16. Global Drug Stability Testing Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Drug Stability Testing Market Share by Region (2027-2032) Table 18. Global Drug Stability Testing Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Drug Stability Testing Revenue Market Share by Players (2021-2026) Table 20. Global Drug Stability Testing Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Drug Stability Testing Key Players Headquarters & Area Served Table 22. Global Drug Stability Testing Players, Product Type & Application Table 23. Global Drug Stability Testing Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Drug Stability Testing by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Drug Stability Testing Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Drug Stability Testing Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Drug Stability Testing Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Drug Stability Testing Revenue Market Share by Type (2021-2026) Table 30. Global Drug Stability Testing Revenue Market Share by Type (2027-2032) Table 31. Global Drug Stability Testing Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Drug Stability Testing Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Drug Stability Testing Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Drug Stability Testing Revenue Market Share by Application (2021-2026) Table 35. Global Drug Stability Testing Revenue Market Share by Application (2027-2032) Table 36. Q Laboratories Company Information Table 37. Q Laboratories Business Overview Table 38. Q Laboratories Drug Stability Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Q Laboratories Drug Stability Testing Product Portfolio Table 40. Q Laboratories Recent Development Table 41. Eurofins BioPharma Company Information Table 42. Eurofins BioPharma Business Overview Table 43. Eurofins BioPharma Drug Stability Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Eurofins BioPharma Drug Stability Testing Product Portfolio Table 45. Eurofins BioPharma Recent Development Table 46. Intertek Group Company Information Table 47. Intertek Group Business Overview Table 48. Intertek Group Drug Stability Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Intertek Group Drug Stability Testing Product Portfolio Table 50. Intertek Group Recent Development Table 51. Labcorp Company Information Table 52. Labcorp Business Overview Table 53. Labcorp Drug Stability Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Labcorp Drug Stability Testing Product Portfolio Table 55. Labcorp Recent Development Table 56. Charles River Laboratories Company Information Table 57. Charles River Laboratories Business Overview Table 58. Charles River Laboratories Drug Stability Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Charles River Laboratories Drug Stability Testing Product Portfolio Table 60. Charles River Laboratories Recent Development Table 61. SGS Company Information Table 62. SGS Business Overview Table 63. SGS Drug Stability Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. SGS Drug Stability Testing Product Portfolio Table 65. SGS Recent Development Table 66. Pacific BioLabs Company Information Table 67. Pacific BioLabs Business Overview Table 68. Pacific BioLabs Drug Stability Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Pacific BioLabs Drug Stability Testing Product Portfolio Table 70. Pacific BioLabs Recent Development Table 71. Element Materials Technology Company Information Table 72. Element Materials Technology Business Overview Table 73. Element Materials Technology Drug Stability Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Element Materials Technology Drug Stability Testing Product Portfolio Table 75. Element Materials Technology Recent Development Table 76. Catalent Company Information Table 77. Catalent Business Overview Table 78. Catalent Drug Stability Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Catalent Drug Stability Testing Product Portfolio Table 80. Catalent Recent Development Table 81. Nelson Labs Company Information Table 82. Nelson Labs Business Overview Table 83. Nelson Labs Drug Stability Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Nelson Labs Drug Stability Testing Product Portfolio Table 85. Nelson Labs Recent Development Table 86. PerkinElmer Company Information Table 87. PerkinElmer Business Overview Table 88. PerkinElmer Drug Stability Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. PerkinElmer Drug Stability Testing Product Portfolio Table 90. PerkinElmer Recent Development Table 91. BioProcess International Company Information Table 92. BioProcess International Business Overview Table 93. BioProcess International Drug Stability Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. BioProcess International Drug Stability Testing Product Portfolio Table 95. BioProcess International Recent Development Table 96. Ardena Company Information Table 97. Ardena Business Overview Table 98. Ardena Drug Stability Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Ardena Drug Stability Testing Product Portfolio Table 100. Ardena Recent Development Table 101. Selvita Company Information Table 102. Selvita Business Overview Table 103. Selvita Drug Stability Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Selvita Drug Stability Testing Product Portfolio Table 105. Selvita Recent Development Table 106. Alcami Company Information Table 107. Alcami Business Overview Table 108. Alcami Drug Stability Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Alcami Drug Stability Testing Product Portfolio Table 110. Alcami Recent Development Table 111. North America Drug Stability Testing Revenue by Type (2021-2026) & (US$ Million) Table 112. North America Drug Stability Testing Revenue by Type (2027-2032) & (US$ Million) Table 113. North America Drug Stability Testing Revenue by Application (2021-2026) & (US$ Million) Table 114. North America Drug Stability Testing Revenue by Application (2027-2032) & (US$ Million) Table 115. North America Drug Stability Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 116. North America Drug Stability Testing Revenue by Country (2021-2026) & (US$ Million) Table 117. North America Drug Stability Testing Revenue by Country (US$ Million) & (2027-2032) Table 118. Europe Drug Stability Testing Revenue by Type (2021-2026) & (US$ Million) Table 119. Europe Drug Stability Testing Revenue by Type (2027-2032) & (US$ Million) Table 120. Europe Drug Stability Testing Revenue by Application (2021-2026) & (US$ Million) Table 121. Europe Drug Stability Testing Revenue by Application (2027-2032) & (US$ Million) Table 122. Europe Drug Stability Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 123. Europe Drug Stability Testing Revenue by Country (2021-2026) & (US$ Million) Table 124. Europe Drug Stability Testing Revenue by Country (US$ Million) & (2027-2032) Table 125. China Drug Stability Testing Revenue by Type (2021-2026) & (US$ Million) Table 126. China Drug Stability Testing Revenue by Type (2027-2032) & (US$ Million) Table 127. China Drug Stability Testing Revenue by Application (2021-2026) & (US$ Million) Table 128. China Drug Stability Testing Revenue by Application (2027-2032) & (US$ Million) Table 129. Asia Drug Stability Testing Revenue by Type (2021-2026) & (US$ Million) Table 130. Asia Drug Stability Testing Revenue by Type (2027-2032) & (US$ Million) Table 131. Asia Drug Stability Testing Revenue by Application (2021-2026) & (US$ Million) Table 132. Asia Drug Stability Testing Revenue by Application (2027-2032) & (US$ Million) Table 133. Asia Drug Stability Testing Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 134. Asia Drug Stability Testing Revenue by Region (US$ Million) & (2021-2026) Table 135. Asia Drug Stability Testing Revenue by Region (US$ Million) & (2027-2032) Table 136. SAMEA Drug Stability Testing Revenue by Type (2021-2026) & (US$ Million) Table 137. SAMEA Drug Stability Testing Revenue by Type (2027-2032) & (US$ Million) Table 138. SAMEA Drug Stability Testing Revenue by Application (2021-2026) & (US$ Million) Table 139. SAMEA Drug Stability Testing Revenue by Application (2027-2032) & (US$ Million) Table 140. SAMEA Drug Stability Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 141. SAMEA Drug Stability Testing Revenue by Country (2021-2026) & (US$ Million) Table 142. SAMEA Drug Stability Testing Revenue by Country (US$ Million) & (2027-2032) Table 143. Research Programs/Design for This Report Table 144. Authors List of This Report Table 145. Secondary Sources Table 146. Primary Sources List of Figures Figure 1. Drug Stability Testing Image Figure 2. Global Drug Stability Testing Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drug Stability Testing Market Size Share 2021 VS 2025 VS 2032 Figure 4. Drug Substances Image Figure 5. Finished Drug Image Figure 6. Global Drug Stability Testing Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Drug Stability Testing Market Size Share 2021 VS 2025 VS 2032 Figure 8. Pharmaceutical Companies Image Figure 9. Biopharmaceutical and Vaccine Companies Image Figure 10. Advanced Therapies Companies Image Figure 11. Others Image Figure 12. Global Drug Stability Testing Market Size (US$ Million) & (2021-2032) Figure 13. Global Drug Stability Testing Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Drug Stability Testing Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Drug Stability Testing Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Drug Stability Testing Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Drug Stability Testing Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Drug Stability Testing Revenue Market Share by Type (2021-2032) Figure 20. Global Drug Stability Testing Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Drug Stability Testing Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Drug Stability Testing Revenue Market Share by Application (2021-2032) Figure 23. North America Drug Stability Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Drug Stability Testing Revenue Share by Type (2021-2032) Figure 25. North America Drug Stability Testing Revenue Share by Application (2021-2032) Figure 26. North America Drug Stability Testing Revenue Share by Country (2021-2032) Figure 27. United States Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Drug Stability Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Drug Stability Testing Revenue Share by Type (2021-2032) Figure 32. Europe Drug Stability Testing Revenue Share by Application (2021-2032) Figure 33. Europe Drug Stability Testing Revenue Share by Country (2021-2032) Figure 34. Germany Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Drug Stability Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Drug Stability Testing Revenue Share by Type (2021-2032) Figure 44. China Drug Stability Testing Revenue Share by Application (2021-2032) Figure 45. Asia Drug Stability Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Drug Stability Testing Revenue Share by Type (2021-2032) Figure 47. Asia Drug Stability Testing Revenue Share by Application (2021-2032) Figure 48. Asia Drug Stability Testing Revenue Share by Region (2021-2032) Figure 49. Japan Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Drug Stability Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Drug Stability Testing Revenue Share by Type (2021-2032) Figure 57. SAMEA Drug Stability Testing Revenue Share by Application (2021-2032) Figure 58. SAMEA Drug Stability Testing Revenue Share by Country (2021-2032) Figure 59. Brazil Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Drug Stability Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Drug Substances
  • Finished Drug
Applications
  • Pharmaceutical Companies
  • Biopharmaceutical and Vaccine Companies
  • Advanced Therapies Companies
  • Others
Companies covered
  • Q Laboratories
  • Eurofins BioPharma
  • Intertek Group
  • Labcorp
  • Charles River Laboratories
  • SGS
  • Pacific BioLabs
  • Element Materials Technology
  • Catalent
  • Nelson Labs
  • PerkinElmer
  • BioProcess International
  • Ardena
  • Selvita
  • Alcami

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Drug Stability Testing Market by Type
  3. 1.2.1 Global Drug Stability Testing Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Drug Substances
  5. 1.2.3 Finished Drug
  6. 1.3 Drug Stability Testing Market by Application
  7. 1.3.1 Global Drug Stability Testing Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Pharmaceutical Companies
  9. 1.3.3 Biopharmaceutical and Vaccine Companies
  10. 1.3.4 Advanced Therapies Companies
  11. 1.3.5 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Drug Stability Testing Market Dynamics
  1. 2.1 Drug Stability Testing Industry Trends
  2. 2.2 Drug Stability Testing Industry Drivers
  3. 2.3 Drug Stability Testing Industry Opportunities and Challenges
  4. 2.4 Drug Stability Testing Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Drug Stability Testing Market Perspective (2021-2032)
  2. 3.2 Global Drug Stability Testing Growth Trends by Region
  3. 3.2.1 Global Drug Stability Testing Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Drug Stability Testing Market Size by Region (2021-2026)
  5. 3.2.3 Global Drug Stability Testing Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Drug Stability Testing Revenue by Players
  2. 4.1.1 Global Drug Stability Testing Revenue by Players (2021-2026)
  3. 4.1.2 Global Drug Stability Testing Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Drug Stability Testing Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Drug Stability Testing Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Drug Stability Testing Key Players Headquarters & Area Served
  7. 4.4 Global Drug Stability Testing Players, Product Type & Application
  8. 4.5 Global Drug Stability Testing Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Drug Stability Testing Market CR5 and HHI
  11. 4.6.3 2025 Drug Stability Testing Tier 1, Tier 2, and Tier 3
5 Drug Stability Testing Market Size by Type
  1. 5.1 Global Drug Stability Testing Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Drug Stability Testing Revenue by Type (2021-2032)
  3. 5.3 Global Drug Stability Testing Revenue Market Share by Type (2021-2032)
6 Drug Stability Testing Market Size by Application
  1. 6.1 Global Drug Stability Testing Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Drug Stability Testing Revenue by Application (2021-2032)
  3. 6.3 Global Drug Stability Testing Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Q Laboratories
  2. 7.1.1 Q Laboratories Company Information
  3. 7.1.2 Q Laboratories Business Overview
  4. 7.1.3 Q Laboratories Drug Stability Testing Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Q Laboratories Drug Stability Testing Product Portfolio
  6. 7.1.5 Q Laboratories Recent Developments
  7. 7.2 Eurofins BioPharma
  8. 7.2.1 Eurofins BioPharma Company Information
  9. 7.2.2 Eurofins BioPharma Business Overview
  10. 7.2.3 Eurofins BioPharma Drug Stability Testing Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Eurofins BioPharma Drug Stability Testing Product Portfolio
  12. 7.2.5 Eurofins BioPharma Recent Developments
  13. 7.3 Intertek Group
  14. 7.3.1 Intertek Group Company Information
  15. 7.3.2 Intertek Group Business Overview
  16. 7.3.3 Intertek Group Drug Stability Testing Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Intertek Group Drug Stability Testing Product Portfolio
  18. 7.3.5 Intertek Group Recent Developments
  19. 7.4 Labcorp
  20. 7.4.1 Labcorp Company Information
  21. 7.4.2 Labcorp Business Overview
  22. 7.4.3 Labcorp Drug Stability Testing Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Labcorp Drug Stability Testing Product Portfolio
  24. 7.4.5 Labcorp Recent Developments
  25. 7.5 Charles River Laboratories
  26. 7.5.1 Charles River Laboratories Company Information
  27. 7.5.2 Charles River Laboratories Business Overview
  28. 7.5.3 Charles River Laboratories Drug Stability Testing Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Charles River Laboratories Drug Stability Testing Product Portfolio
  30. 7.5.5 Charles River Laboratories Recent Developments
  31. 7.6 SGS
  32. 7.6.1 SGS Company Information
  33. 7.6.2 SGS Business Overview
  34. 7.6.3 SGS Drug Stability Testing Revenue and Gross Margin (2021-2026)
  35. 7.6.4 SGS Drug Stability Testing Product Portfolio
  36. 7.6.5 SGS Recent Developments
  37. 7.7 Pacific BioLabs
  38. 7.7.1 Pacific BioLabs Company Information
  39. 7.7.2 Pacific BioLabs Business Overview
  40. 7.7.3 Pacific BioLabs Drug Stability Testing Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Pacific BioLabs Drug Stability Testing Product Portfolio
  42. 7.7.5 Pacific BioLabs Recent Developments
  43. 7.8 Element Materials Technology
  44. 7.8.1 Element Materials Technology Company Information
  45. 7.8.2 Element Materials Technology Business Overview
  46. 7.8.3 Element Materials Technology Drug Stability Testing Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Element Materials Technology Drug Stability Testing Product Portfolio
  48. 7.8.5 Element Materials Technology Recent Developments
  49. 7.9 Catalent
  50. 7.9.1 Catalent Company Information
  51. 7.9.2 Catalent Business Overview
  52. 7.9.3 Catalent Drug Stability Testing Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Catalent Drug Stability Testing Product Portfolio
  54. 7.9.5 Catalent Recent Developments
  55. 7.10 Nelson Labs
  56. 7.10.1 Nelson Labs Company Information
  57. 7.10.2 Nelson Labs Business Overview
  58. 7.10.3 Nelson Labs Drug Stability Testing Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Nelson Labs Drug Stability Testing Product Portfolio
  60. 7.10.5 Nelson Labs Recent Developments
  61. 7.11 PerkinElmer
  62. 7.11.1 PerkinElmer Company Information
  63. 7.11.2 PerkinElmer Business Overview
  64. 7.11.3 PerkinElmer Drug Stability Testing Revenue and Gross Margin (2021-2026)
  65. 7.11.4 PerkinElmer Drug Stability Testing Product Portfolio
  66. 7.11.5 PerkinElmer Recent Developments
  67. 7.12 BioProcess International
  68. 7.12.1 BioProcess International Company Information
  69. 7.12.2 BioProcess International Business Overview
  70. 7.12.3 BioProcess International Drug Stability Testing Revenue and Gross Margin (2021-2026)
  71. 7.12.4 BioProcess International Drug Stability Testing Product Portfolio
  72. 7.12.5 BioProcess International Recent Developments
  73. 7.13 Ardena
  74. 7.13.1 Ardena Company Information
  75. 7.13.2 Ardena Business Overview
  76. 7.13.3 Ardena Drug Stability Testing Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Ardena Drug Stability Testing Product Portfolio
  78. 7.13.5 Ardena Recent Developments
  79. 7.14 Selvita
  80. 7.14.1 Selvita Company Information
  81. 7.14.2 Selvita Business Overview
  82. 7.14.3 Selvita Drug Stability Testing Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Selvita Drug Stability Testing Product Portfolio
  84. 7.14.5 Selvita Recent Developments
  85. 7.15 Alcami
  86. 7.15.1 Alcami Company Information
  87. 7.15.2 Alcami Business Overview
  88. 7.15.3 Alcami Drug Stability Testing Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Alcami Drug Stability Testing Product Portfolio
  90. 7.15.5 Alcami Recent Developments
8 North America
  1. 8.1 North America Drug Stability Testing Revenue (2021-2032)
  2. 8.2 North America Drug Stability Testing Revenue by Type (2021-2032)
  3. 8.2.1 North America Drug Stability Testing Revenue by Type (2021-2026)
  4. 8.2.2 North America Drug Stability Testing Revenue by Type (2027-2032)
  5. 8.3 North America Drug Stability Testing Revenue Share by Type (2021-2032)
  6. 8.4 North America Drug Stability Testing Revenue by Application (2021-2032)
  7. 8.4.1 North America Drug Stability Testing Revenue by Application (2021-2026)
  8. 8.4.2 North America Drug Stability Testing Revenue by Application (2027-2032)
  9. 8.5 North America Drug Stability Testing Revenue Share by Application (2021-2032)
  10. 8.6 North America Drug Stability Testing Revenue by Country
  11. 8.6.1 North America Drug Stability Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Drug Stability Testing Revenue by Country (2021-2026)
  13. 8.6.3 North America Drug Stability Testing Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Drug Stability Testing Revenue (2021-2032)
  2. 9.2 Europe Drug Stability Testing Revenue by Type (2021-2032)
  3. 9.2.1 Europe Drug Stability Testing Revenue by Type (2021-2026)
  4. 9.2.2 Europe Drug Stability Testing Revenue by Type (2027-2032)
  5. 9.3 Europe Drug Stability Testing Revenue Share by Type (2021-2032)
  6. 9.4 Europe Drug Stability Testing Revenue by Application (2021-2032)
  7. 9.4.1 Europe Drug Stability Testing Revenue by Application (2021-2026)
  8. 9.4.2 Europe Drug Stability Testing Revenue by Application (2027-2032)
  9. 9.5 Europe Drug Stability Testing Revenue Share by Application (2021-2032)
  10. 9.6 Europe Drug Stability Testing Revenue by Country
  11. 9.6.1 Europe Drug Stability Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Drug Stability Testing Revenue by Country (2021-2026)
  13. 9.6.3 Europe Drug Stability Testing Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Drug Stability Testing Revenue (2021-2032)
  2. 10.2 China Drug Stability Testing Revenue by Type (2021-2032)
  3. 10.2.1 China Drug Stability Testing Revenue by Type (2021-2026)
  4. 10.2.2 China Drug Stability Testing Revenue by Type (2027-2032)
  5. 10.3 China Drug Stability Testing Revenue Share by Type (2021-2032)
  6. 10.4 China Drug Stability Testing Revenue by Application (2021-2032)
  7. 10.4.1 China Drug Stability Testing Revenue by Application (2021-2026)
  8. 10.4.2 China Drug Stability Testing Revenue by Application (2027-2032)
  9. 10.5 China Drug Stability Testing Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Drug Stability Testing Revenue (2021-2032)
  2. 11.2 Asia Drug Stability Testing Revenue by Type (2021-2032)
  3. 11.2.1 Asia Drug Stability Testing Revenue by Type (2021-2026)
  4. 11.2.2 Asia Drug Stability Testing Revenue by Type (2027-2032)
  5. 11.3 Asia Drug Stability Testing Revenue Share by Type (2021-2032)
  6. 11.4 Asia Drug Stability Testing Revenue by Application (2021-2032)
  7. 11.4.1 Asia Drug Stability Testing Revenue by Application (2021-2026)
  8. 11.4.2 Asia Drug Stability Testing Revenue by Application (2027-2032)
  9. 11.5 Asia Drug Stability Testing Revenue Share by Application (2021-2032)
  10. 11.6 Asia Drug Stability Testing Revenue by Country
  11. 11.6.1 Asia Drug Stability Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Drug Stability Testing Revenue by Country (2021-2026)
  13. 11.6.3 Asia Drug Stability Testing Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Drug Stability Testing Revenue (2021-2032)
  2. 12.2 SAMEA Drug Stability Testing Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Drug Stability Testing Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Drug Stability Testing Revenue by Type (2027-2032)
  5. 12.3 SAMEA Drug Stability Testing Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Drug Stability Testing Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Drug Stability Testing Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Drug Stability Testing Revenue by Application (2027-2032)
  9. 12.5 SAMEA Drug Stability Testing Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Drug Stability Testing Revenue by Country
  11. 12.6.1 SAMEA Drug Stability Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Drug Stability Testing Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Drug Stability Testing Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst